Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Post Essential Thrombocythemia Myelofibrosis (ET-MF): early-phase trial registry
1 of 1 indexed Post Essential Thrombocythemia Myelofibrosis (ET-MF) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #11,370 of 28,707 conditions by registered trial count.
1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count
Post Essential Thrombocythemia Myelofibrosis (ET-MF): 1 US clinical trial tracked, 1 recruiting.
Post Essential Thrombocythemia Myelofibrosis (ET-MF) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Icahn School of Medicine at Mount Sinai, running 1 of these trials.
Enrollment posture brief
Registry condition post-essential-thrombocythemia-myelofibrosis-et-mf
OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Post Essential Thrombocythemia Myelofibrosis (ET-MF) lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Post Essential Thrombocythemia Myelofibrosis (ET-MF) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Post Essential Thrombocythemia Myelofibrosis (ET-MF) is recruiting above its size-band peers.
1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Post Essential Thrombocythemia Myelofibrosis (ET-MF) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Post Essential Thrombocythemia Myelofibrosis (ET-MF) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Post Essential Thrombocythemia Myelofibrosis (ET-MF) page
1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Post Essential Thrombocythemia Myelofibrosis (ET-MF) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Icahn School of Medicine at Mount Sinai sponsors the most Post Essential Thrombocythemia Myelofibrosis (ET-MF) trials on record, review their full trial history before evaluating a specific study. See Icahn School of Medicine at Mount Sinai's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Post Essential Thrombocythemia Myelofibrosis (ET-MF) condition card totals 1 registered trials; most-linked intervention reparixin; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.